4Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. J Am Coil Cardiol,2003 ,41:1633 - 1652.
5Fuster V,Ryde'n LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J, 2001,22: 1852-1923
6Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. J Am Coll Cardiol,2003,41 : 1633-1652.
7Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med,2000,160:41-46.
8Atrial Fibrillation Investigators. Risk factors forstrokean defficacy of antihrom boticthera pyinatrial fibrillati on : analy sisof pooled data fromfiv erandomiz dcontr olledtrials.Archlntern Med ,2001,154 : 1449-1457.
9HirshJ, FusterV, AnsellJ, etal. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy, JAmColl Cardio1,2003,41 : 1633-1652.
10GoldsteinJA. Clinical relevance of gelletic polymorphism since the human CYP2C subfamily. BrJ ClinP harmacol.2001,52(4) :349-55.
